We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants Accelerated Approval to Blincyto for Pediatric Leukemia
FDA Grants Accelerated Approval to Blincyto for Pediatric Leukemia
FDA granted accelerated approval to Amgen’s Blincyto (blinatumomab) for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.